Medicrea raises over $22M toward spinal rod commercialization

A UNiD spinal rod--Courtesy of Medicrea

Medicrea announced agreements which raised €20 million ($22.4 million) to support the U.S. market penetration and international commercialization of its UNiD Patient-Specific Rods. Medicrea also announced Richard Kienzle will take on the role of chief commercial officer and business development officer, and will also join the board of directors.

Courtesy of Medicrea
Medicrea earned FDA approval for its UNiD rods back in 2014. The rods are customizable to match a patient's specific spinal alignment. This helps to decrease the risk of spinal implant failure, improve success rate of global sagittal patient alignment and offers more efficiency in the operating room.

At this point, Medicrea has collaborated in almost 900 UNiD surgeries. Medicrea also offers end-to-end analytical service to help develop collaboration between itself and surgeons and providers for improved patient care.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

“There are now significant forces aligning behind Medicrea’s efforts to bring personalized, value-based solutions to Spine: We own a unique market space with an unrivaled technology in UNiD,” said Denys Sournac, president and CEO of Medicrea, in the announcement.

The financing is made up of €5 million in equity and four-year, 6.75% €15 million convertible bonds. Investors include Anthyrium Capital Management, which is solely responsible for the convertible bonds.

“With UNiD, surgeons can more precisely achieve their surgical goals and restore proper sagittal alignment for their patients, a predictor of success for complex spine procedures,” said Richard Pines, partner at Athyrium, in the announcement. “The technology’s personalized services and innovative approach to spine surgery offer significant growth potential with tens of thousands of complex multi-level fusions occurring each year in the U.S.”

Pines also noted that Athyrium is looking forward to the appointment of Kienzle, who has 25 years of executive sales management within orthopedic companies.

“I believe Medicrea to be a true pioneer in the global spine industry with data-driven, value- based, next-generation and comprehensive solutions for the Personalized Complex Spine Market. The U.S. market opportunity is profound,” Kienzle said in the announcement. “I look forward to working with the entire Medicrea team to deploy these significant resources efficiently and effectively as Medicrea reshapes the Complex Spine paradigm and rapidly expands its commercialization efforts with UNiD and the entire suite of personalized and optimized technologies.”

- here's the press release

Related Article: 
FDA clears first patient-specific spinal rod

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.